Opinion|Videos|March 13, 2025
Emerging ADC Clinical Trial Evidence in Breast Cancer Treatment
Panelists discuss how emerging antibody-drug conjugates (ADCs) in metastatic breast cancer (mBC) treatment demonstrate innovation through optimized drug-to-antibody ratios, novel payloads, and targeted approaches to different breast cancer subtypes. Key trials explore combinations with established therapies and potential for improved tolerability profiles. Additional notable studies include comparative effectiveness research between approved ADCs and investigation of biomarker-driven patient selection strategies to maximize therapeutic benefit while minimizing adverse effects.
Advertisement
Episodes in this series
Video content above has been prompted by the following:
- How do emerging ADCs in clinical trials (eg, DB-1303/BNT323, patritumab deruxtecan, zanidatamab) demonstrate innovative approaches to treating mBC?
- Aside from emerging ADCs, please describe other clinical trials that may be of interest to pharmacists in this space (eg, head-to-head comparisons of approved ADCs).
Advertisement
Related to this article
EMBER-3 data show switching to the combination at progression nearly doubled PFS versus imlunestrant alone in ESR1-mutated advanced breast cancer.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
5